Type 1 diabetes cure·closes in 76mo

Will the FDA approve a cure for Type 1 Diabetes before 2033?

YES means Before 2033

24h volume
0
9,827 lifetime
Open interest
4,988
Spread
22 × 35 at the touch
24h range
Chance of YES
39%

A YES contract costs 39¢ and pays $1 if it happens.

NO
61%

costs 62¢

YES bid / ask
38¢ / 39¢
NO bid / ask
61¢ / 62¢
What Galdor thinks

An independent read of this market

1Reads the rules literallySettlement source, close time, and the edge cases that flip an outcome.
2Checks the tape and the webOrder book, flow, price history, then targeted searches with sources.
3Gives a straight answerA probability with a band, and one of four calls: YES, NO, wait, or stay out.

Generated by an AI analyst from live exchange data and public web sources. Research and analytics, not investment advice. Markets can move after this was written.

Price history

YES price per candle with the bid/ask band, volume underneath. Times in UTC.

Not enough history to chart.

Order book

Resting orders, both sides shown as YES prices. Bars are size.

Yes ask (no bid)SizeYes
  • ask1189¢
  • ask1180¢
  • ask6475¢
  • ask1,04670¢
  • ask2.0560¢
  • ask50044¢
  • ask40242¢
  • ask3539¢
spreadmid 39¢
  • bid2238¢
  • bid50036¢
  • bid0.1934¢
  • bid3.0427¢
  • bid1825¢
  • bid7511¢
  • bid55010¢
  • bid1,296
Yes bid (no ask)SizeYes

How this market resolves

Verbatim from Kalshi. Read this before the price.

If the FDA approves a cure for Type 1 diabetes before Jan 1, 2033, then the market resolves to Yes.

opened
Jun 27, 2025 · 8:45 PM UTC
closes
Jan 1, 2033 · 4:59 AM UTC · may close early
settles by
Jan 1, 2033 · 3:00 PM UTC
ticker
KXFDATYPE1DIABETES-33
Trade it on kalshi.com

This event

Outcomes in this event settle independently.

This is the only market in Will the FDA approve a cure for Type 1 diabetes before 2033?.

Prices are YES cost in cents and approximate the market’s implied probability. Data is read live from the Kalshi Trade API on every page load. galdor.xyz places no orders and holds no positions. Research and analytics, not investment advice.